Uncategorized 13 Jan 2025 LTS and BioNet Win U.S. BARDA Patch Forward Prize Competition LTS and BioNet Win U.S. BARDA Patch Forward Prize Competition Andernach – LTS, a leading pharmaceutical technology company, and BioNet,… BioNet
Uncategorized 21 Dec 2024 A reduced-dose recombinant pertussis vaccine booster in Thai adolescents: a phase 2/3, observer-blinded, randomised controlled, non-inferiority trial A reduced-dose recombinant pertussis vaccine booster in Thai adolescents: a phase 2/3, observer-blinded, randomised controlled, non-inferiority trial Pertussis, also known… BioNet
Uncategorized 05 Dec 2024 Pertussis Immunity 5 Years After Booster Vaccination With Recombinant Pertussis Vaccines Pertussis Immunity 5 Years After Booster Vaccination With Recombinant Pertussis Vaccines Pertussis remains one of the least controlled vaccine-preventable diseases.… BioNet
Uncategorized 31 Jul 2024 BioNet’s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA) BioNet’s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA) "Monovalent recombinant acellular pertussis vaccine proven to significantly boost immunity… BioNet
Uncategorized 25 Jul 2024 Transplacental transfer of maternal antibodies following immunization with recombinant pertussis vaccines during pregnancy: Real-world evidence Pertussis, caused by Bordetella pertussis, is a highly contagious respiratory disease that poses a significant risk to young infants, resulting in both severe morbidity… BioNet
Uncategorized 20 Jul 2023 Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing… Pantitra Laohatranon
Uncategorized 11 Jul 2023 A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women… Pantitra Laohatranon
Uncategorized 01 Apr 2022 A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age A phase 2 randomized-controlled safety and immunogenicity trial evaluating different doses of recombinant acellular pertussis vaccine containing genetically-inactivated pertussis toxin… Pantitra Laohatranon
Uncategorized 20 Jul 2021 Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines Recombinant pertussis vaccines inducing long-lasting immune responses could help to control the rise in pertussis. We here report on persisting antibody responses 2 and 3 years after booster vaccination with a new generation recombinant acellular pertussis vaccine. Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen… Pantitra Laohatranon
Uncategorized 07 Jul 2021 Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines Recombinant pertussis vaccines inducing long-lasting immune responses could help to control the rise in pertussis. We here report on persisting… Pantitra Laohatranon
